{
    "eid": "2-s2.0-85092053634",
    "title": "Pembrolizumab- A nd ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: A case report",
    "cover-date": "2020-09-29",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Diabetic ketoacidosis",
        "Immune checkpoint inhibitors",
        "Immune-related adverse event",
        "Immunotherapy",
        "Isolated adrenocorticotropic hormone deficiency"
    ],
    "authors": [
        "Thachanun Porntharukchareon",
        "Borwonkhun Tontivuthikul",
        "Nattaya Sintawichai",
        "Panudda Srichomkwun"
    ],
    "citedby-count": 7,
    "ref-count": 11,
    "ref-list": [
        "Endocrine toxicity of cancer immunotherapy targeting immune checkpoints",
        "PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?",
        "A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors",
        "Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors",
        "Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review",
        "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: Presentation, management and outcome",
        "Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: A case report and review of the literature",
        "Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors",
        "Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab",
        "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}